Literature DB >> 11205358

A prospective study on the prognosis of multiple sclerosis.

M P Amato1, G Ponziani.   

Abstract

Two hundred and twenty-four patients at their first diagnosis of multiple sclerosis (MS) were prospectively followed for a mean period of 9.78 years. We considered as endpoints the time to reach non-reversible disability levels corresponding to EDSS scores of 4.0 and 6.0, and the beginning of a secondary progressive phase in the relapsing-remitting subgroup of patients. An initially progressive course and higher basal EDSS scores proved to be the best predictors of unfavorable prognosis. A greater number of functional systems involved at onset as well as higher residual deficits in pyramidal, visual, sphincteric and cerebellar systems were other factors predictive of a poor outcome, whereas sensory system involvement turned out to be favorable. A longer first inter-attack interval was associated with a better prognosis. However, overall number of relapses in the first two years of the disease was of no prognostic value. The presence of oligoclonal banding in the cerebrospinal fluid and a cerebral MRI exam strongly suggestive or suggestive of MS in the early phases of the disease were associated with a higher probability of a worse outcome.

Entities:  

Mesh:

Year:  2000        PMID: 11205358     DOI: 10.1007/s100720070021

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  27 in total

Review 1.  Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Authors:  Bharath Wootla; Jens O Watzlawik; Nikolaos Stavropoulos; Nathan J Wittenberg; Harika Dasari; Murtada A Abdelrahim; John R Henley; Sang-Hyun Oh; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Opin Biol Ther       Date:  2016-03-10       Impact factor: 4.388

Review 2.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

3.  Early predictive factors of disability in CIDP.

Authors:  Emanuele Spina; Antonietta Topa; Rosa Iodice; Stefano Tozza; Lucia Ruggiero; Raffaele Dubbioso; Marcello Esposito; Dario Bruzzese; Lucio Santoro; Fiore Manganelli
Journal:  J Neurol       Date:  2017-08-02       Impact factor: 4.849

Review 4.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

5.  Evidence of diffuse cerebellar neuroinflammation in multiple sclerosis by 11C-PBR28 MR-PET.

Authors:  Valeria T Barletta; Elena Herranz; Costantina A Treaba; Russell Ouellette; Ambica Mehndiratta; Marco L Loggia; Eric C Klawiter; Carolina Ionete; Sloane A Jacob; Caterina Mainero
Journal:  Mult Scler       Date:  2019-04-11       Impact factor: 6.312

Review 6.  Genomic, proteomic, and systems biology approaches in biomarker discovery for multiple sclerosis.

Authors:  Carol Chase Huizar; Itay Raphael; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2020-09-20       Impact factor: 4.868

7.  Clinical and cognitive implications of cerebrospinal fluid oligoclonal bands in multiple sclerosis patients.

Authors:  Maria Anagnostouli; Foteini Christidi; Ioannis Zalonis; Chryssoula Nikolaou; Dimitrios Lyrakos; Nikolaos Triantafyllou; Ioannis Evdokimidis; Constantinos Kilidireas
Journal:  Neurol Sci       Date:  2015-07-01       Impact factor: 3.307

8.  A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease.

Authors:  Jessica Mandrioli; Patrizia Sola; Roberta Bedin; Mariaelena Gambini; Elisa Merelli
Journal:  J Neurol       Date:  2008-06-13       Impact factor: 4.849

Review 9.  The pros and cons of early treatment of relapsing forms of multiple sclerosis.

Authors:  Xavier Montalban
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

10.  Demyelinating events in early multiple sclerosis have inherent severity and recovery.

Authors:  E M Mowry; M Pesic; B Grimes; S Deen; P Bacchetti; E Waubant
Journal:  Neurology       Date:  2009-02-17       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.